AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03245567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLM
Description: Participants will take the PLM on the visual estimation of LVEF. They will also take a pretest, a post-test and a delayed test at 6 months.
Study NCT03245567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre, post, delayed test
Description: Participants will perform a pretest, a posttest and a delayed test at 6 months.
Study NCT02520895 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood samplings
Description: patients will have blood samplings at different time : D0: day of inclusion = day of the first course of chemotherapy or the 1st day of the confirmation of the diagnosis (group 8) M3: 3 months (+/- 1 month) after the start of treatment (except for group 8) M6: 6 months (+/- 1 month) after the start of treatment or after the 1st day of the confirmation of the diagnosis (group 8) M12 : 12 months after the start of treatment (group 6 and 7) M18: 18 months (+/- 1 month) after the start of treatment or after the 1st day of the confirmation of the diagnosis (group 8) R: to relapse if it occurs before 18 months or at the time of first treatment if it occurs before 18 months (group 8)
Study NCT03224819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emerfetamab
Description: Administered by intravenous (IV) infusion.
Study NCT01567267 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental educational intervention
Description: Educational intervention consisting of a 4-day-course in Evidence-based Medicine and Good Scientific Practice combined with the method of Problem-based Learning.
Study NCT01567267 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard educational intervention
Description: Educational intervention on the didactics of biology (4-day-course) not containing elements of Evidence-based Medicine, Good Scientific Practice or Problem-based learning.
Study NCT00000258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous oxide 10% & placebo
Study NCT00000258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous oxide 20% & placebo
Study NCT00000258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous oxide 30% & placebo
Study NCT00000258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous oxide 40% and placebo
Study NCT02952404 — intervention group
Intervention type: PROCEDURE
Intervention: Educational workshop
Description: The educational workshop for improved perineal support during vaginal delivery
Study NCT03623165 — intervention group
Intervention type: DEVICE
Intervention: Cordella™ Heart Failure System
Description: The Cordella™ Heart Failure System electronically transfers communications and data from a set of medical devices in a heart failure patient's home to a database for storage, retrieval, and display to healthcare providers.
Study NCT00404612 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PO BID
Study NCT00404612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LX211
Description: 0.2 mg/kg, twice a day (BID)
Study NCT00404612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LX211
Description: 0.4 mg/kg, twice a day (BID)
Study NCT00404612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LX211
Description: 0.6 mg/kg, twice a day (BID)
Study NCT02562677 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Trigeminal Nerve Stimulation
Study NCT03210194 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Neonatal Resuscitation Training
Description: Theoretical and practical training on basic and advanced neonatal resuscitation skills, directed to personnel from remote health centers using Standard Training
Study NCT03210194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MP-ICT Neonatal Resuscitation Training
Description: Theoretical and practical training on basic and advanced neonatal resuscitation skills, directed to personnel from remote health centers using Information and Communication Technologies
Study NCT01724099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Euiiyin-tang
Description: Korean medicinal herbal drug
Study NCT01724099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug, same odor and formula as Euiiyin-tang
Study NCT01886053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faropenem（high dose group）
Description: dosage form: Injection dosage:2400 mg frequency: Three times a day
Study NCT01886053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faropenem（low-dose group)
Description: dosage form: Injection dosage:2400 mg frequency: twice a day
Study NCT01886053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem
Description: dosage form: Injection dosage:1000 mg frequency: once a day
Study NCT02170077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: BIA 2-093 (tablets) administered at increasing daily doses of 400 mg, 800 mg and 1200 mg once-daily or twice-daily, oral route
Study NCT02170077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets administered orally
Study NCT03557034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kardia Monitoring
Description: Kardia Mobile is an FDA approved device that allows one lead ECG recording for 30 seconds using the patient's smart phone. The device has a built-in algorithm that detects AF. KardiaPro is a secure platform that allows the physician to access the patient's recording at any time. The platform can also be programmed to send a notification to the healthcare provider if AF is detected by the software.
Study NCT01338623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tansulosine
Description: capsule 0,4 mg
Study NCT03537859 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented Reality
Description: Augmented reality children books. The books will have special markers. The device's camera will read the marker and show 2d and 3D animations with the book's theme.
Study NCT03537859 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Non Augmented Reality
Description: Augmented reality book without electronic device. Since no electronic device will be provided, the children will not be able to see any augmented reality features of the book, making it a conventional children's book.
Study NCT03453073 — intervention group
Intervention type: BEHAVIORAL
Intervention: chocolate consumption level
Description: level of consumption of 1 oz. of chocolate, as assessed at baseline
Study NCT03453073 — intervention group
Intervention type: OTHER
Intervention: physician diagnosis of first occurrence of serious chronic disease
Study NCT01421927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Start between Day+100 and Day+120 post-transplant~- Initial dose: 5 mg/day every day~In the absence of thrombocytopenia \< 75000/mm3 or neutropenia \< 1000/mm3 (with or without G-CSF), increase to the upper level than the ongoing one every third month up to the maximal dose of 15 mg/day every day.~- Duration~* until persistent stringent complete response for 3 months~* or progression defined by IMWG criteria12~* or unacceptable toxicity~* or one year after transplant
Study NCT03945591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3 mg/m2 IV 6 hours after graft infusion and 72 hours thereafter.
Study NCT03945591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg IV over 2 hours on Day +3 and +4
Study NCT02982590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 5 MG Oral Tablet [ELIQUIS]
Description: Apixaban is licensed for treatment of deep vein thrombosis and pulmonary embolism. Hence, a good study drug for left ventricular thrombosis for possibility of a new indication.
Study NCT02982590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin Sodium
Description: as controlled arm since warfarin is the standard therapy for LV thrombus
Study NCT00785044 — intervention group
Intervention type: DRUG
Intervention: I-123 mIBG
Description: This was an observational study. Participants were previously dosed in separate study.
Study NCT01628107 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epoetin Hospira
Description: Intravenous (IV) injection
Study NCT02047682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biopsychosocial
Study NCT02047682 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reference
Study NCT01976520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oncoquest-CLL vaccine
Description: Comparison of 4 different dose levels of Oncoquest-CLL vaccine: 100 micrograms (mcg)/0.2 milliliters (mL), 200 mcg/0.4 mL, 375 mcg/0.75 mL, and 500 mcg/mL. Patients will receive a total of 5 doses of vaccines; the first 2 doses separated by 2 week intervals and the last 3 doses by 1 month intervals. Vaccine will be given by sc injections in 2 sites in upper arms or legs.
Study NCT02278562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anakinra
Description: 100 mg in syringes; administered subcutaneously 3 times a week for 12 weeks (3 months)
Study NCT04330404 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive strategy training
Description: The Cognitive strategy training, including awareness enhancement, cognitive-related education, discussion of everyday cognitive difficulties, generation of cognitive strategies, cognitive strategy practice, and homework assignments
Study NCT02278562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: actos
Description: 30 mg capsules; administered orally 1 capsule per day for 12 weeks (3 months)
Study NCT02278562 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsules and injection
Study NCT01830855 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rLP2086
Description: 0.5 mL dose, given at 0, 2 and 6 months (lot 1)
Study NCT01830855 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rLP2086
Description: 0.5 mL dose, given at 0, 2 and 6 months (lot 2)
Study NCT01830855 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rLP2086
Description: 0.5 mL dose, given at 0, 2 and 6 months (lot 3)
Study NCT01830855 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix (HAV)
Description: 0.5 mL dose or 1.0 mL dose dependent on age given at month 0 and 6.
Study NCT01830855 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: 0.5 mL dose of sterile normal saline for injection.
Study NCT03832803 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empty bladder
Description: No drinking protocol.
Study NCT03832803 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Full bladder
Description: Followed drinking protocol
Study NCT02107495 — intervention group
Intervention type: DEVICE
Intervention: Samsung LABGEO IVD-A20 CHF Test
Study NCT05500820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIN-107
Description: A repeat oral dose of CIN-107 once daily for 10 days.
Study NCT05500820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: A repeat oral dose of matching placebo once daily for 10 days.
Study NCT00382239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide (LY2148568)
Description: subcutaneous injection twice daily, 5 mcg for 4 weeks, then 10 mcg for 8 weeks
Study NCT00382239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide (LY2148568)
Description: subcutaneous injection twice daily, 5 mcg for 4 weeks, then 5 mcg for 8 weeks
Study NCT00382239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide (LY2148568)
Description: subcutaneous injection twice daily, 2.5 mcg for 4 weeks, then 2.5 mcg for 8 weeks
Study NCT00382239 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection twice daily, 0.02 mL to 0.04 mL
Study NCT02895620 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Xpert bladder Test
Description: Xpert test positive or negative on urine samples of NMIBC patients treated by BCG
Study NCT04330404 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: group interactive game
Description: The active control group will receive group interactive game, including table games and games using songs, balloons, newspapers and so on.
Study NCT03585764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOv19-BBz CAR T cells
Description: intraperitoneally administered lentiviral transduced MOv19-BBz CAR T cells with or without cyclophosphamide + fludarabine as lymphodepleting chemotherapy.
Study NCT03585764 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha Folate Receptor expression test
Description: Patients will first be pre-screened for alpha folate receptor expression. The test for alpha folate receptor expression is a laboratory developed test+, developed and conducted by the Hospital of the University of Pennsylvania Pathology and Laboratory Medicine lab to determine subject eligibility. This test is not an approved FDA device and its use is investigational.
Study NCT04659876 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: clinical features and laboratory values
Description: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
Study NCT00967070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: 25 mg nicotine patch applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.
Study NCT00967070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Patch
Description: Placebo patch applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.
Study NCT00621751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: 800 mg daily
Study NCT00621751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01937936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Family caregivers in the CBT group will receive 8 1-hour weekly Cognitive Behavioral Therapy (CBT) sessions, which will take place in their home.
Study NCT01937936 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Family caregivers in the Education group will receive 8 1-hour weekly sessions of general health education on selected topics, which will take place in their home.
Study NCT03805997 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dietary advice
Description: participants will benefit of dietary device 30-minute dietary advice carried out by a doctor at the University Hospital of Rennes, in order to provide nutritional advice adapted to pregnant women.
Study NCT03805997 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dietary advice
Description: participants will benefit of dietary device 30-minute dietary advice carried out by a doctor at the University Hospital of Rennes, in order to provide nutritional advice adapted to pregnant women.
Study NCT03805997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consumption of Bleu-Blanc-Coeur products
Description: consumption of Bleu-Blanc-Cœur products from the 29th week of amenorrhea to the 45th postpartum day
Study NCT03805997 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No consumption of Bleu-Blanc-Coeur products
Description: no consumption of Bleu-Blanc-Cœur products from the 29th week of amenorrhea to the 45th postpartum day. This group will receive Système U vouchers.
Study NCT03805997 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Blood sample
Description: the fatty acid profile of the women red blood cells of the woman wil be test at the inclusion and at 21 days post-partum
Study NCT03805997 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: the fatty acid profile of the women red blood cells of the woman wil be test at the inclusion and at 21 days post-partum
Study NCT03805997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contact
Description: Participants of the group A will be contacted by phone,sms, mail by a technician every 15 days from 7th month of pregnancy to the 8th month of pregnancy and then every week from the 9th month of pregnancy to the 45th postpartum day (except the week of childbirth), in order to collect their consumption data of the delivered food products.
Study NCT03805997 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: food questionnaire
Description: Participants will have to complete a food questionnaire at the inclusion and at 21 days post-partum
Study NCT03805997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: food questionnaire
Description: Participants will have to complete a food questionnaire at the inclusion and at 21 days post-partum
Study NCT03805997 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: newborn faeces sample
Description: Newborn faeces sample will be collected at 21 Days post partum
Study NCT03805997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: newborn faeces sample
Description: Newborn faeces sample will be collected at 21 Days post partum
Study NCT03805997 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: breast milk sample
Description: Breast milk sample will be collected at 21 days and 45 days post partum
Study NCT03805997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breast milk sample
Description: Breast milk sample will be collected at 21 days and 45 days post partum
Study NCT01048749 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aquatic vertical suspension.
Description: Subject is suspended in a warm water deep pool with two pool noodles around the subject and directly under the axilla. Five pound weights are placed on the ankle and the subject maintains this unloaded position for 15 minutes.
Study NCT01048749 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: land-based supine flexion
Description: The subject will lay supine with the legs supported by a foam wedge with hips flexed to 90 degrees and knees flexed to 65 degrees. They will maintain this unloaded position for 15 minutes.
Study NCT00739011 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SleepStyle 254/244 CPAP series CPAP humidifier
Description: Therapeutic CPAP pressure will be determined for individual subjects during the titration portion of an overnight sleep study. This pressure will range from 4 to 20 cmH20
Study NCT02163187 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of the InterStimTM
Study NCT02163187 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MSK BFI questionnaires
Study NCT02163187 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Low Anterior Resection Score (LARS) questionnaires
Study NCT02163187 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The EuroQOL5D questionnaires
Study NCT02163187 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Fecal incontinence Quality of Life Scale (FIQOL) questionnaires
Study NCT02571127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hidra1
Description: Parameters: Vaginal health index (VHI) : The parameter of efficiency : a vaginal moisture ; Will Measured through the VHI : 1 = none / inflamed area ; 2 = no / NOT inflamed surface ; 3 = minimal, 4 = moderate and 5 = normal.~Will be described through the Media and Standard Deviation or median and interquartile rank , as Minimum and Maximum.~Scala: pH tape: It will be measured by its own value. Questionnaire: Sexual Function Index female (FSFI): internationally validated questionnaire with single answers for patient.
Study NCT02774512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Each patient will receive nilotinib 800 mg/day every day for 7 days. Study treatment will be taken twice a day (400 mg - 2 capsules) by oral route with an interval of approximately 12 hours between two doses and should not be taken with food. The entire capsule should be swallowed with water. No food should be consumed for 2 hours before taking the drug and for at least 1 hour after it.
Study NCT04195048 — intervention group
Intervention type: OTHER
Intervention: Risk factors
Description: Risk factors: modifiable and unmodifiable risk factors
Study NCT01101438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: Given orally
Study NCT01101438 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally